Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134671 | 1.00 | ESR2 (0.36) | ESR2ALDH1A1HPGDRECQLHSD17B10 | |
| SCHEMBL4460095 | 1.00 | ESR2 (0.36) | ESR2ALDH1A1HPGDRECQLHSD17B10 | |
| SCHEMBL13711175 | 0.92 | GAA (0.37) | ESR2ALDH1A1HPGDRECQLHSD17B10 | |
| SCHEMBL14501401 | 0.88 | ALDH1A1 (0.34) | ESR2ALDH1A1HPGDRECQLHSD17B10 | |
| SCHEMBL27029447 | 0.85 | ADORA1 (0.40) | ESR2ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL27028450 | 0.85 | ADORA1 (0.40) | ESR2ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL13315685 | 0.85 | ADORA1 (0.40) | ESR2ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL13355699 | 0.85 | ADORA1 (0.40) | ESR2ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL18299260 | 0.84 | ESR2 (0.36) | ESR2ALDH1A1HPGDRECQLHSD17B10 | |
| SCHEMBL18299258 | 0.84 | ESR2 (0.36) | ESR2ALDH1A1HPGDRECQLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640699-A2 | BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012066488-A2 | BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-7592360-B2 | Parkinson's disease, Alzheimer's disease, migraine, epilepsy, and pain | MERCK & CO., INC. (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1648882-B1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME LLC | 2007-06-28 | — | — | US | disclosed |
| EP-1648882-A1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2004108705-A1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | GRIN2B, GRIN1, GRIN2A | ESR2 705/4885ALDH1A1 3147/4885HPGD 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.